| Intervention | Cost | Source |
|---|---|---|
| ICS | £295 | PSSRU 2013,72 NHS Supply Chain Catalogue April 2014,223 BNF 67,150 NICE Clinical Guideline CG174,210 Crotty 200670 |
| PCS | £88 | PSSRU 2013,72 NHS Supply Chain Catalogue April 2014223 |
| ICS+PCS | £350 | PSSRU 2013,72 NHS Supply Chain Catalogue April 2014,223 BNF 67,150 NICE Clinical Guideline CG174,210 Crotty 200670 |
| TXA (high risk subgroup) | £19 | Total dose 6000 mg, slow IV injection followed by continuous IV infusion. BNF 67,150 eMIT July 201,462 NHS Supply Chain Catalogue April 2014,223 NICE Clinical Guideline CG174210 |
| TXA (moderate risk subgroup) | £9 | Total dose 3000 mg slow IV injection. BNF 67,150 eMIT July 201462 |
| ICS +TXA | £314 | Sum of ICS and TXA (high risk subgroup) |
Abbreviations: BNF = British National Formulary; eMIT = Electronic Market Information Tool; ICS = intra-operative cell salvage; IV = intravenous; PSSRU = Personal Social Services Research Unit; PCS = post-operative cell salvage; TXA = tranexamic acid
From: 6, Alternatives to blood transfusion for patients having surgery: Cell salvage and tranexamic acid
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.